iPACK Block With Dexamethasone For Total Knee Replacement
Primary Purpose
Knee Osteoarthritis, Acute Pain, Anesthesia, Local
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
ropivacaine 0.25% with epinephrine and 6mg dexamethasone
Saline
Sponsored by
About this trial
This is an interventional treatment trial for Knee Osteoarthritis focused on measuring acute postoperative pain, knee replacement
Eligibility Criteria
Inclusion Criteria:
- Having total knee arthroplasty at UC San Diego
- Plan to receive single shot adductor canal injection preoperatively
- Plan to receive spinal anesthetic with or without sedation for TKA surgery
Exclusion Criteria:
- Pregnancy
- Inability to communicate with anesthesia provider and/or investigators
- Severe renal, hepatic, cardiac disease
- Chronic high-dose opioid use (defined as daily use for more than 4 weeks prior to surgery of at least the equivalent of 20 mg oxycodone)
- BMI > 45 kg/m2
- Allergy to study medications (lidocaine, bupivacaine)
- Incarceration
Sites / Locations
- University of California, San DiegoRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Active Treatment
Placebo
Arm Description
Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
Outcomes
Primary Outcome Measures
Average Opioid Use POD 0-1
Average Opioid Use
Average Pain Score at Rest
Average Pain Score at Rest
Average Pain Score with Motion
Average Pain Score with Motion
Secondary Outcome Measures
Gait Distance
Distance patient can walk on with physical therapy (PT)
Knee Range of motion
Range of motion with Physical Therapy (PT)
Length of stay
From admission to hospital for surgery to discharge
Average Opioid Use postoperative day (POD) 1-2
Average Opioid Use in morphine equivalents
Average Pain Score, postoperative day (POD) 1-2.
Average Pain Score
Full Information
NCT ID
NCT04917055
First Posted
May 28, 2021
Last Updated
June 6, 2022
Sponsor
University of California, San Diego
1. Study Identification
Unique Protocol Identification Number
NCT04917055
Brief Title
iPACK Block With Dexamethasone For Total Knee Replacement
Official Title
Impact of Adding iPACK Block With Dexamethasone to Existing APS Multimodal Analgesia Protocol for Patients Undergoing Total Knee Arthroplasty
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 7, 2021 (Actual)
Primary Completion Date
June 7, 2022 (Anticipated)
Study Completion Date
August 1, 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Diego
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Comparing the pain control outcomes for patients undergoing total knee arthroplasty (TKA) with either: 1) adductor canal single shot injection plus placebo iPACK injection or 2) adductor canal single shot injection plus bupivacaine and dexamethasone iPACK injection.
There are two surgical approaches for TKA 1) open 2) ROSA robotic assisted. Both follow the same pain management pathway. We plan to enroll patient undergoing either surgical procedure.
Detailed Description
This will be a single-center (UCSD), randomized blinded investigation.
Enrollment. Consenting adults undergoing TKA will be offered enrollment. Study inclusion will be proposed to eligible patients prior to surgery. If a patient desires study participation, written, informed consent will be obtained using a current UCSD IRB-approved ICF.
Preoperative Procedures. Following written, informed consent, we will record baseline anthropomorphic information (age, sex, height, and weight) that is already provided by all patients having surgery. After consenting and prior to surgery, patients will be randomized (utilizing sealed envelopes with 1:1 ratio) to either single-shot adductor canal block with sham iPACK block or single-shot adductor canal block with local anesthetic + dexamethasone iPACK block. A regional anesthesia fellow, not participating in the study, will open the sealed envelope and prepare the iPACK solution to be used accordingly.
Current Standard Care: Currently, all patients undergoing TKA receive preoperative adductor canal block as well as multimodal pain regimen managed by APS. They all receive intraoperative intraarticular injections by the surgical team. Spinal vs general anesthesia is decided at the discretion of the intraoperative anesthesiologist along with patient preferences and relevant contraindications. The only difference for subjects participating in the study (vs those not participating) will be that they will be randomized to receive an additional nerve block for posterior knee pain.
Adductor canal single shot block + Sham group: In the preoperative holding area, all subjects in this cohort will have a peripheral intravenous (IV) catheter inserted, standard noninvasive monitors applied, supplemental oxygen administered via a nasal cannula or face mask, and positioned supine. Midazolam and fentanyl (IV) will be titrated for patient comfort, while ensuring that patients remain responsive to verbal cues. The area of insertion will be cleaned with chlorhexidine gluconate and isopropyl alcohol (ChloraPrep One-Step, Medi-Flex Hospital Products, Inc., Overland Park, KS, USA). A single shot adductor canal block will be performed under ultrasound guidance with 20 mls of 0.25% ropivacaine with 1:400,000 epinephrine. A sensory level to ice will be confirmed and decided to be adequate if positive based on the discretion of the attending anesthesiologist. A Sham iPACK block will then be performed under ultrasound guidance, where 20 mls of 0.9% normal saline with 1:400,000 epi (as a vascular marker) is injected between the popliteal artery and the posterior aspect of the femoral condyle. As is standard for all TKA at our institution, all patients will additionally receive an intraoperative intraarticular injection by the surgical team of 50 mls 0.25% bupivacaine + 30 mg Ketorolac + 0.25mg epinephrine, which will occur at least 60 minutes after preoperative perineural injections.
Adductor canal single shot block + iPACK group: In the preoperative holding area, all subjects in this cohort will have a peripheral intravenous (IV) catheter inserted, standard noninvasive monitors applied, supplemental oxygen administered via a nasal cannula or face mask, and positioned supine. Midazolam and fentanyl (IV) will be titrated for patient comfort, while ensuring that patients remain responsive to verbal cues. The area of insertion will be cleaned with chlorhexidine gluconate and isopropyl alcohol (ChloraPrep One-Step, Medi-Flex Hospital Products, Inc., Overland Park, KS, USA). A single shot adductor canal block will be performed under ultrasound guidance with 20 mls of 0.25% ropivacaine with 1:400,000 epinephrine. A sensory level to ice will be confirmed and decided to be adequate if positive based on the discretion of the attending anesthesiologist. An iPACK block will then be performed under ultrasound guidance, where 20 mls of 0.25% ropivacaine with 1:400,000 epinephrine and 6mg dexamethasone is injected between the popliteal artery and the posterior aspect of the femoral condyle. As is standard for all TKA at our institution, all patients will additionally receive an intraoperative intraarticular injection by the surgical team of 50 mls 0.25% bupivacaine + 30 mg Ketorolac + 0.25mg epinephrine, which will occur at least 60 minutes after preoperative perineural injections.
Additional Postoperative Pain Interventions: Intraoperatively, spinal anesthesia versus general anesthesia will be decided at the discretion of the operating room anesthesiologist. Postoperatively, both groups will be started on the same multimodal oral regimen and followed by our anesthesiology led acute pain team.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis, Acute Pain, Anesthesia, Local, Regional Anesthesia
Keywords
acute postoperative pain, knee replacement
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized
Masking
ParticipantOutcomes Assessor
Masking Description
Care provider and investigator will know if patient received SHAM or bupivacaine iPACK, but everyone else will be blinded
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Active Treatment
Arm Type
Active Comparator
Arm Description
Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus distal iPACK (between femoral condyles) single shot with long acting local anesthetic (ropivacaine) plus dexamethasone
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Adductor Canal Single Shot with long acting local anesthetic (ropivacaine) plus iPACK single shot with normal saline
Intervention Type
Drug
Intervention Name(s)
ropivacaine 0.25% with epinephrine and 6mg dexamethasone
Intervention Description
Regional Nerve block behind the knee for posterior knee pain following total knee arthroplasty using ultrasound guidance, to be done distally between femoral chondyles
Intervention Type
Drug
Intervention Name(s)
Saline
Intervention Description
Injection of Saline behind knee using ultrasound guidance
Primary Outcome Measure Information:
Title
Average Opioid Use POD 0-1
Description
Average Opioid Use
Time Frame
Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement
Title
Average Pain Score at Rest
Description
Average Pain Score at Rest
Time Frame
Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement
Title
Average Pain Score with Motion
Description
Average Pain Score with Motion
Time Frame
Postoperative day (POD) 0-1, as defined by 24 hours after iPACK block placement
Secondary Outcome Measure Information:
Title
Gait Distance
Description
Distance patient can walk on with physical therapy (PT)
Time Frame
POD0-1 (first PT session)
Title
Knee Range of motion
Description
Range of motion with Physical Therapy (PT)
Time Frame
POD0-1 (first PT session)
Title
Length of stay
Description
From admission to hospital for surgery to discharge
Time Frame
Total number of days requiring hospitalization for surgical procedure. Up to 1 month
Title
Average Opioid Use postoperative day (POD) 1-2
Description
Average Opioid Use in morphine equivalents
Time Frame
Postoperative day (POD) 1-2.
Title
Average Pain Score, postoperative day (POD) 1-2.
Description
Average Pain Score
Time Frame
Postoperative day (POD) 1-2.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Having total knee arthroplasty at UC San Diego
Plan to receive single shot adductor canal injection preoperatively
Plan to receive spinal anesthetic with or without sedation for TKA surgery
Exclusion Criteria:
Pregnancy
Inability to communicate with anesthesia provider and/or investigators
Severe renal, hepatic, cardiac disease
Chronic high-dose opioid use (defined as daily use for more than 4 weeks prior to surgery of at least the equivalent of 20 mg oxycodone)
BMI > 45 kg/m2
Allergy to study medications (lidocaine, bupivacaine)
Incarceration
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Engy Said, MD
Phone
6195436240
Email
esaid@health.ucsd.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Engy Said, MD
Organizational Affiliation
University of California, San Diego
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Diego
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Engy M Said, MD
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
iPACK Block With Dexamethasone For Total Knee Replacement
We'll reach out to this number within 24 hrs